<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>bcr197</ui>
   <ji>BCJ</ji>
   <fm>
      <dochead>Meeting abstract</dochead>
      <bibl>
         <title>
            <p>The Swedish Two-County Trial 20-years on: updated mortality results and new insights from long-term follow-up</p>
         </title>
         <aug>
            <au id="A1">
               <snm>Tab&#225;r</snm>
               <fnm>L</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A2">
               <snm>Duffy</snm>
               <fnm>SW</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A3">
               <snm>Vit&#225;k</snm>
               <fnm>B</fnm>
               <insr iid="I3"/>
            </au>
            <au id="A4">
               <snm>Chen</snm>
               <fnm>H-H</fnm>
               <insr iid="I4"/>
            </au>
            <au id="A5">
               <snm>Krusemo</snm>
               <fnm>UB</fnm>
               <insr iid="I5"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Department of Mammography, Central Hospital, Falun, Sweden</p>
            </ins>
            <ins id="I2">
               <p> Biostatistics Unit, Medical Research Council, Cambridge, UK</p>
            </ins>
            <ins id="I3">
               <p>Department of Medical Radiology, University Hospital of Link&#246;ping, Link&#246;ping, Sweden</p>
            </ins>
            <ins id="I4">
               <p>Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan</p>
            </ins>
            <ins id="I5">
               <p>Information Technology Support Department, Uppsala University, Uppsala, Sweden</p>
            </ins>
         </insg>
         <source>Breast Cancer Res</source>
         <supplement>
            <title>
               <p>Symposium Mammographicum 2000</p>
            </title>
            <note>Meeting abstracts</note>
         </supplement>
         <conference>
            <title>
               <p>Symposium Mammographicum 2000</p>
            </title>
            <location>York, UK</location>
            <date-range>4&#8211;6 October 2000</date-range>
         </conference>
         <issn>1465-5411</issn>
         <pubdate>2000</pubdate>
         <volume>2</volume>
         <issue>Suppl 2</issue>
         <fpage>A3</fpage>
         <xrefbib>
            <pubid idtype="doi">10.1186/bcr197</pubid>
         </xrefbib>
      </bibl>
      <history>
         <pub>
            <date>
               <day>4</day>
               <month>10</month>
               <year>2000</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2000</year>
         <collab>Current Science Ltd</collab>
      </cpyrt>
   </fm>
   <meta>
      <classifications>
         <classification type="BMC" subtype="old_arx_id">bcr-2-s2-03</classification>
      </classifications>
   </meta>
   <bdy>
      <sec>
         <st>
            <p>Full text</p>
         </st>
         <p>The Swedish Two-County Trial is a randomized controlled study of invitation to breast cancer screening. It was initiated in late 1977. The follow-up to the end of 1998 provides results at approximately the twentieth anniversary of the trial. A significant decrease in breast cancer death among women invited to screening was published 7-8 years after randomization and at 20-year follow up there is a significant 32% reduction in mortality associated with invitation to screening. The advent of screen-film mammographic screening with the ability to detect potentially fatal tumors at an early stage provides an opportunity to study the natural history of breast cancer at an earlier phase in its development than was possible in the past. Our findings show that breast cancer is not a systemic disease at its inception, but is a progressive disease and its development can be arrested by screening. Detection of &lt;15 mm and lymph node negative invasive tumors will save lives and confer an opportunity for less radical treatment. </p>
         <p>Mammography is clearly a very useful tool, not only for early detection of cancers but also for successful discrimination between the highly fatal and nonfatal cancers. The four mammographic prognostic features will be presented.</p>
      </sec>
   </bdy>
</art>
